

Datasheet for ABIN2855104

**anti-DOK1 antibody**

3 Images

1 Publication

[Go to Product page](#)

## Overview

Quantity:	100 µL
Target:	DOK1
Reactivity:	Human
Host:	Rabbit
Clonality:	Polyclonal
Conjugate:	This DOK1 antibody is un-conjugated
Application:	Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

## Product Details

Immunogen:	Recombinant protein encompassing a sequence within the center region of human p62Dok. The exact sequence is proprietary.
Isotype:	IgG
Cross-Reactivity:	Human
Characteristics:	Rabbit Polyclonal antibody to DOK1 (docking protein 1, 62 kDa (downstream of tyrosine kinase 1)) DOK1 antibody [N1C1]
Purification:	Purified by antigen-affinity chromatography.

## Target Details

Target:	DOK1
Alternative Name:	docking protein 1 ( <a href="#">DOK1 Products</a> )

## Target Details

**Background:** Docking protein 1 is constitutively tyrosine phosphorylated in hematopoietic progenitors isolated from chronic myelogenous leukemia (CML) patients in the chronic phase. It may be a critical substrate for p210(bcr/abl), a chimeric protein whose presence is associated with CML. Docking protein 1 contains a putative pleckstrin homology domain at the amino terminus and ten PXXP SH3 recognition motifs. Docking protein 2 binds p120 (RasGAP) from CML cells. It has been postulated to play a role in mitogenic signaling.

**Molecular Weight:** 52 kDa

**Gene ID:** 1796

**UniProt:** [Q99704](#)

## Application Details

**Application Notes:** WB: 1:500-1:3000. IHC-P: 1:100-1:1000. Optimal dilutions/concentrations should be determined by the researcher. Not tested in other applications.

**Comment:** Positive Control: Raji  
Validation: Orthogonal

**Restrictions:** For Research Use only

## Handling

**Format:** Liquid

**Concentration:** 1 mg/mL

**Buffer:** 0.1M Tris-Glycine ( pH 7), 20 % Glycerol, 0.01 % Thimerosal


**Preservative:** Thimerosal (Merthiolate)

**Precaution of Use:** This product contains Thimerosal (Merthiolate): a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

**Storage:** 4 °C,-20 °C


**Storage Comment:** Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4°C. For long-term storage, aliquot and store at -20°C or below. Avoid multiple freeze-thaw cycles.

Product cited in: Sarin, Engel, Rothweiler, Cinatl, Michaelis, Frötschl, Fröhlich, Kalayda: "Key Players of Cisplatin Resistance: Towards a Systems Pharmacology Approach." in: **International journal of molecular sciences**, Vol. 19, Issue 3, (2018) ([PubMed](#)).




Western Blotting

**Image 1.** WB Image Sample (30 ug of whole cell lysate) A: Raji 10% SDS PAGE antibody diluted at 1:1000



Immunohistochemistry

**Image 2.** IHC-P Image Immunohistochemical analysis of paraffin-embedded H661 xenograft, using DOK1, antibody at 1:500 dilution.



Western Blotting

**Image 3.** mRNA expression (all n = 6) of HRas, MAPK14 (p38), CCL2, DOK1 and PTK2B related to GAPDH mRNA expression, protein expression of HRas (n = 6), p38 (n = 6), CCL2 (n = 4), DOK1 (n = 7-8) and PTK2B (n = 3) related to GAPDH expression in A549 () and A549rCDDP2000 () before (ctrl) and after treatment with 11 μM cisplatin (11) or 34 μM cisplatin (34) presented as mean ± SEM, as well as representative Western blots. \* p < 0.05, \*\* p < 0.01, \*\*\* p <

0.01. - figure provided by CiteAb. Source: PMID29518977